Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Takeda UK Ltd, 1 Kingdom Street, London, W2 6BD, United Kingdom
Fosrenol 750 mg oral powder.
| Pharmaceutical Form |
|---|
|
Oral Powder. White to off-white powder. |
Each sachet contains 750 mg lanthanum (as lanthanum carbonate hydrate).
Excipient(s) with known effect: Each sachet also contains 641.7 mg dextrates, containing glucose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lanthanum |
Lanthanum is indicated as a phosphate binding agent for use in the control of hyperphosphataemia. |
| List of Excipients |
|---|
|
Dextrates (hydrated) |
2.1 g of oral powder in sachets formed from a polyethylene terephthalate/aluminium/polyethylene laminate.
Pack size: 90 sachets (Outer carton contains 9 cartons of 10 sachets).
Takeda UK Ltd, 1 Kingdom Street, London, W2 6BD, United Kingdom
PL 16189/0141
Date of first authorisation: 13/04/2012
Date of latest renewal: 19/03/2012
| Drug | Countries | |
|---|---|---|
| FOSRENOL | Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
